Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron's Evkeeza Approved For Ultra-Rare Genetic High Cholesterol – And Priced To Match

Executive Summary

Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.

You may also be interested in...



Keeping Track: Regeneron Wins US FDA OK For Evkeeza, New Libtayo Uses; G1 Cosela Cleared

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

A Slimmed-Down Pfizer Sets A New R&D Goal: 25 Launches By 2025

The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.

After Two Jury Verdicts, Court Finds Repatha Patents Invalid

Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel